This article was originally published in The Gray Sheet
Executive SummaryPrivate placement raises $4 mil. for Cohesion's NeuColl osteobiologics subsidiary to fund a pivotal clinical study of its NeuVisc osteoarthritis treatment and expand Collagraft synthetic bone graft substitute commercialization. The single injection NeuVisc treatment, if approved by FDA, would compete with currently available hyaluronic acid-based synovial fluid supplements that require multiple intra-articular knee injections. Also under development is NeuGraft, a second generation fully resorbable bone graft substitute and High Density Collagen for a variety of potential resorbable fixation applications. The financing reduces Cohesion's ownership position in NeuColl to "under 50%," Cohesion notes
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.